Harrow Health, Inc. Stock News

Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and pat...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of...

Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addre...

Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and re...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSR...

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2...

Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Ope...